α7 nicotinic acetylcholine receptor modulation of accumbal dopamine release covaries with novelty seeking.
SUD
individual differences
nicotine
voltammetry
vulnerability
Journal
The European journal of neuroscience
ISSN: 1460-9568
Titre abrégé: Eur J Neurosci
Pays: France
ID NLM: 8918110
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
03
02
2022
received:
25
06
2021
accepted:
07
02
2022
pubmed:
11
2
2022
medline:
12
4
2022
entrez:
10
2
2022
Statut:
ppublish
Résumé
Heightened novelty-seeking phenotypes are associated with a range of behavioural traits including susceptibility to drug use. These relationships are recapitulated in preclinical models, where rats that exhibit increased exploratory activity in novel environments (high responders-HR) acquire self-administration of psychostimulants more rapidly compared to rats that display low novelty exploration (low responders-LR). Dopamine release dynamics in the nucleus accumbens (NAc) covaries with response to novelty, and differences in dopaminergic signalling are thought to be a major underlying driver of the link between novelty seeking and drug use vulnerability. Accumbal dopamine release is controlled by local microcircuits including modulation through glutamatergic and nicotinic acetylcholine receptor (nAChR) systems, but whether these mechanisms contribute to disparate dopamine signalling across novelty phenotypes is unclear. Here, we used ex vivo voltammetry in the NAc of rats to determine if α7 nAChRs contribute to differential dopamine dynamics associated with individual differences in novelty exploration. We found that blockade of α7 nAChRs attenuates tonic dopamine release evoked by low-frequency stimulations across phenotypes but that phasic release is decreased in LRs while HRs are unaffected. These stimulation frequency- and phenotype-dependent effects result in a decreased dynamic range of release exclusively in LRs. Furthermore, we found that differential α7 modulation of dopamine release in LRs is dependent on AMPA but not NMDA receptors. These results help to form an understanding of the local NAc microcircuitry and provide a potential mechanism for covariance of dopamine dynamics and sensitivity to the reinforcing effects of drugs of abuse.
Identifiants
pubmed: 35141983
doi: 10.1111/ejn.15620
pmc: PMC9586210
mid: NIHMS1779368
doi:
Substances chimiques
Chrna7 protein, rat
0
Receptors, Nicotinic
0
alpha7 Nicotinic Acetylcholine Receptor
0
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1162-1173Subventions
Organisme : NIAAA NIH HHS
ID : P50 AA026117
Pays : United States
Organisme : NIAAA NIH HHS
ID : F32 AA028162
Pays : United States
Organisme : NIDA NIH HHS
ID : F31 DA053114
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA052460
Pays : United States
Organisme : NIDA NIH HHS
ID : R00 DA031791
Pays : United States
Organisme : NIDA NIH HHS
ID : R00 DA045103
Pays : United States
Organisme : NIDA NIH HHS
ID : P50 DA006634
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA041349
Pays : United States
Informations de copyright
© 2022 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.
Références
Eur J Neurosci. 2021 Mar;53(6):1794-1808
pubmed: 33332672
Cell Rep. 2012 Jul 26;2(1):33-41
pubmed: 22840394
Neuropharmacology. 2017 Nov;126:281-291
pubmed: 28666811
Neuroscience. 1995 Feb;64(3):587-97
pubmed: 7715773
Nature. 2001 Jul 5;412(6842):43-8
pubmed: 11452299
J Neurosci. 2000 Dec 1;20(23):8876-85
pubmed: 11102497
Science. 1997 Mar 14;275(5306):1593-9
pubmed: 9054347
Biol Psychiatry. 2010 Oct 15;68(8):770-3
pubmed: 20678754
Neuropsychopharmacology. 2004 Dec;29(12):2168-79
pubmed: 15292903
Brain Res. 2012 Aug 27;1470:24-34
pubmed: 22765913
J Neurosci. 2010 Mar 3;30(9):3398-408
pubmed: 20203199
Neuroscience. 2012 Jan 3;200:31-41
pubmed: 22079576
J Pharmacol Exp Ther. 2002 Jul;302(1):197-204
pubmed: 12065717
J Neurosci. 2007 Aug 15;27(33):8771-8
pubmed: 17699659
Science. 2008 Jun 6;320(5881):1352-5
pubmed: 18535246
Psychopharmacology (Berl). 2002 Jul;162(3):333-8
pubmed: 12122492
Neuron. 2012 Jul 12;75(1):58-64
pubmed: 22794260
J Neurosci Methods. 2011 Nov 15;202(2):158-64
pubmed: 21392532
Nat Neurosci. 2004 Jun;7(6):581-2
pubmed: 15146187
Pharmacol Biochem Behav. 1989 Mar;32(3):691-7
pubmed: 2662223
Nat Neurosci. 2004 Jun;7(6):583-4
pubmed: 15146188
ACS Chem Neurosci. 2018 Apr 18;9(4):715-724
pubmed: 29161023
Science. 2005 Mar 11;307(5715):1642-5
pubmed: 15761155
Synapse. 1991 Oct;9(2):121-8
pubmed: 1821483
Neuropsychopharmacology. 2012 Jun;37(7):1708-16
pubmed: 22395730
Biochem Pharmacol. 2007 Oct 15;74(8):1235-46
pubmed: 17825262
Science. 1989 Sep 29;245(4925):1511-3
pubmed: 2781295
Neurosci Biobehav Rev. 2009 Jul;33(7):1145-54
pubmed: 19497336
J Neurochem. 1991 Sep;57(3):819-22
pubmed: 1650394
Neuroscience. 2014 Dec 12;282:176-97
pubmed: 25084048
Nat Commun. 2012;3:1172
pubmed: 23132022
Neuroscience. 1992;47(2):333-9
pubmed: 1379352
J Pharmacol Exp Ther. 2009 Dec;331(3):985-97
pubmed: 19729579
Neuropsychopharmacology. 2008 Aug;33(9):2158-66
pubmed: 18033235
Eur J Neurosci. 2013 Aug;38(4):2628-36
pubmed: 23725404
ACS Chem Neurosci. 2013 May 15;4(5):693-703
pubmed: 23581570
Nature. 2011 Jan 6;469(7328):53-7
pubmed: 21150898
Behav Pharmacol. 2009 Jul;20(4):322-9
pubmed: 19571743
Psychopharmacology (Berl). 2001 Nov;158(2):175-80
pubmed: 11702091
Front Hum Neurosci. 2013 Aug 27;7:468
pubmed: 23986674
Neuropsychopharmacology. 2011 Feb;36(3):569-79
pubmed: 20980989
Psychopharmacology (Berl). 2007 Apr;191(3):391-431
pubmed: 17072591
J Neurochem. 2002 Mar;80(6):1071-8
pubmed: 11953457
Mol Pharmacol. 2000 Aug;58(2):312-8
pubmed: 10908298
J Neurochem. 2020 Dec;155(5):475-493
pubmed: 32356315
Nature. 2019 Jun;570(7759):65-70
pubmed: 31118513
Science. 2004 Aug 13;305(5686):1014-7
pubmed: 15310906
J Neurosci. 2009 Apr 1;29(13):4035-43
pubmed: 19339599
J Neurosci. 2001 Mar 1;21(5):1452-63
pubmed: 11222635
Lancet Psychiatry. 2016 Aug;3(8):760-773
pubmed: 27475769
Sci Rep. 2020 Jan 13;10(1):173
pubmed: 31932634
Biochem Pharmacol. 2009 Oct 1;78(7):744-55
pubmed: 19523928
Neuropsychopharmacology. 2020 Jan;45(1):220
pubmed: 31462753
Brain Res. 2013 May 28;1512:37-44
pubmed: 23506787
Cereb Cortex. 2016 Oct 1;26(11):4160-4169
pubmed: 27566978